Backstage @ Upstage

HOST:  Hildy Grossman    CO-HOST:  Jordan Rich GUESTS:   Sahil Patel, MD, Pulmonologist Inflammation is a brilliant lifesaver when you twist an ankle—and a silent danger when your body forgets how to turn it off. In this eye-opening episode of Backstage @ Upstage, host Hildy Grossman sits down with pulmonologist Dr. Sahil Patel to demystify the hidden biological forces shaping our health. Together, they translate complex cellular science and modern environmental hazards—from microplastics and smog to the surge of chronic conditions in younger populations—into clear, practical takeaways. Dr. Patel reveals how short-term healing can mutate into tissue damage, interstitial lung disease, and cancer, while introducing the idea of an immune “thermostat” that balances over-active autoimmune responses against under-active cancer defenses. From cutting-edge diagnostic breakthroughs to next-generation therapies designed to cool down internal inflammation before disease takes hold, this essential conversation offers a masterclass in protecting your body from the inside out. Tune in to discover how disease takes root—and how science is learning to stop it!

HOST:  Hildy Grossman    CO-HOST:  Jordan Rich GUESTS:    John Lamb, Taylor Kirkwood, and Hildy Grossman What does it take to build a musical—and turn personal tragedy into a mission? Join hosts Hildy Grossman & Jordan Rich with guests John Lamb and Taylor Kirkwood. Together, they pull back the curtain on the 20-year journey of Ziegfeld! What started as a Broadway tribute grew into a story of ambition, glamour, and grit. When Hildy faced an unexpected lung cancer diagnosis, the show took on a new purpose. Original composer Seth Rubin completed the score before tragically losing his life to lung cancer. After new script edits, composer Taylor Kirkwood joined the team to write two final songs. Now, Upstage Lung Cancer presents an exclusive workshop/concert on August 9, 2026. ULC is the only organization using performing arts to fund early-detection research. With over $4.5 million raised to date, art and community are actively saving lives. Audience feedback will help shape Ziegfeld! while every ticket supports the cause. Tune in for an intimate conversation on passion, heartbreaking loss, and creative victory. Discover how a shared love for the theater transformed into a lifesaving movement. Listen now and learn how you can be part of this unforgettable win-win evening!

HOST:  Hildy Grossman CO-HOST:  Jordan Rich GUESTS:   Joan H. Schiller, MD and Francine Jacobson, MD, MPH In 2021, the World Health Organization issued a stark warning: climate change is the single biggest health threat facing humanity. And yet, the public often perceives climate change as an abstract concept or a political debate, not a health problem. It’s time to change this perception. Alarmingly, lung cancer deaths have surged by nearly 30% since 2007. Every year we experience accelerating heat waves, wildfires, droughts, and extreme weather events. Moreover, all these changes impact cancer occurrence and care. Our guests probe deeply into this serious problem, looking at causes and possible solutions.    Dr. Schiller explains how her global group, OUCH (Oncologists United for Climate and Health) fights back using education and advocating for policy change to protect cancer patients and us all from the dangers of climate change. Meanwhile, Dr. Jacobson supports increasing access to life-saving lung cancer screenings for underserved, high-risk communities. She suggests steps to accomplish this by expanding criteria for screenings. Are we ready to treat climate change and air pollution like the medical emergency it is? Tune in to uncover the link between our environment and cancer - and how we can fight back.

HOST:  Hildy Grossman CO-HOST:  Jordan Rich GUESTS: Kyle Concannon, MD, Samantha Murrell, Bianca Bye and Leah Phillips The face of lung cancer is changing. No longer viewed simply as a “smoker’s disease” that only impacts older adults, there is a rising and concerning trend of younger adults and non-smokers being diagnosed with advanced disease.  Our guests today have so much light to shine on this issue. In this powerhouse episode, we hear from Samantha Murrell, diagnosed with Stage 4 with a HER2 biomarker at age 37. She notes that her way of coping with her diagnosis was to learn everything possible about her disease. She tells how hope comes with new, cutting-edge drugs targeting HER2 because they allow her to live a full and active life.   Our guest, Leah Phillips, a mother of three young children, also was shocked by her diagnosis of Stage 4 lung cancer at 43. She tells how she joined Bianca Bye, who faced the advanced diagnosis and tragic loss of both parents, within months of each other, to lung cancer. Leah and Bianca joined forces to create the Young Lung Cancer Initiative. Oncologist, Dr. Kyle Concannon notes how these three resilient women are finding meaning in advocacy as they work to transform suffering into meaning by helping others. This is an unforgettable, action-driven look at hope, survival, and taking control.

HOST: Hildy Grossman, CO-HOST: Jordan Rich GUESTS: Lecia Sequist, MD and Allison Chang, MD, Ph.D. We are building on our previous "All in the Family" episode, with Jaclyn Lo Piccolo, MD, Ph.D., Pasi Janne, MD, Ph.D., of the Dana Farber Cancer Institute and Jill Feldman from EGFR Resisters. To look deeper into how a family history of lung cancer might increase the risk for other members, we invited Drs. Lecia Sequist and Allison Chang from Mass General Hospital to discuss their latest research on risk factors and the role of family history in lung cancer. We examine the current array of diagnostic tools—from CT scans to germline genetic testing—and the mystery of why some family members are more vulnerable to environmental pollutants than others. Tune in to see how Drs. Sequist and Chang are using AI- driven CT analysis to identify risk in those with a family history of lung cancer and learn if you qualify to participate in their

HOST: Hildy Grossman CO-HOST, Jordan Rich Guests: Sachi Badola and Lauren Coye Think you’re too young for lung cancer? Think again! This week, we’re joined by two incredible young women who are highlighting the realities and breaking the stigma. Our first guest, Lauren Coye, shares her grueling journey to finally being diagnosed with lung cancer.  After being told she had recurring upper respiratory infections, starting at age 14, Lauren’s persistence led to the discovery 10 years later that saved her life. Her story is a testament to the life-saving power of self- advocacy. Our next guest, Sachi Badola, is a pre-med student at Dartmouth College in New Hampshire. On top of that, she is taking over the reins to become the producer of Upstage Lung Cancer’s 10th annual Sing Out! concert on April 4, 2026. Bringing together eight a cappella groups to sing out about lung cancer, the concert will also be live-streamed and afterwards be available on YouTube and on our website. Both young women continue to raise awareness of lung cancer as Board Members of Upstage Lung Cancer. From the doctor’s office to the center stage, we’re exploring how the next generation can raise their voices to fund research and demand better care. It’s time to listen.

HOST:  Hildy Grossman, CO-HOST: Jordan Rich GUEST: Sumati Ram-Mohan, Vice President of Upstage Lung Cancer Why did singer and cabaret performer Hildy Grossman launch Upstage Lung Cancer 18 years ago? In this episode, Hildy describes how a fluke accident resulted in early detection of her lung cancer and put her on a life-changing path. When faced with an early diagnosis, Hildy didn’t just ask "Why me?"—she asked, "What now?" She realized that while anyone with lungs can get lung cancer, not everyone has a stage to fight it. Thus, Upstage Lung Cancer was created as the only lung cancer organization to exclusively produce concerts and the performing arts to raise awareness, reduce stigma and fund cutting edge medical research. In a meeting of Art & Science, our guest, Sumati Ram-Mohan, a scientist and dancer, shares her story of how and why she reached out to Hildy. Now the Vice President of Upstage Lung Cancer, Sumati discusses how her experience in lung research and her passion for the stage help move this organization forward. Among other things, this podcast series, now ranked in the top 5 out of 40 lung cancer podcasts, was created to be both engaging, enjoyable and informative. They discuss almost two decades of outreach and impact, ending with a look ahead to this year's Fall Concert – an evening of joy aimed at this difficult disease. We thank our sponsors Lilly, Bristol Meyers Squibb, Revolution Medicines, Boehringer Ingelheim, and Takeda for their generous support of our podcast series Backstage @ Upstage.

HOST: Hildy Grossman CO-HOST, Jordan Rich Guests: Justin Gainor, MD, Director of Targeted Immunotherapy at the Massachusetts General Hospital and David Barbie, MD, Director of the Barbie Lab at Dana Farber Cancer Institute Targeting Innate Immunity in Cancer Lung cancer has long been one of the most complex and difficult cancers to treat. But what if we could outsmart it—not just with surgery, chemotherapy, or radiation, but by training the immune system itself? This episode explores a revolutionary question: Could a vaccine change the future of lung cancer? To shed light on answers to this question are Dr. Justin Gainor, whose interest is in vaccine development, and Dr. David Barbie, who returns to Backstage @ Upstage to explain how the immune system responds to cancer. Our renowned guests describe the challenges of creating a therapeutic vaccine and why a preventative vaccine is less likely to succeed. They detail how the immune system’s delicate operations need to be understood to successfully develop a vaccine to treat lung cancer. Moreover, you’ll want to hear about the groundbreaking promise of “personalized vaccines” tailored to an individual’s unique genomic markers, and how these cutting-edge vaccines will change the future of oncology forever.   

HOST: Hildy Grossman, CO-HOST: Jordan Rich GUESTS: Jessica Lin, MD., Sarah Craig, Frank Marotta Hearing the diagnosis of Stage 4 can be devastating, but today, it is no longer the final word. More people are living with Stage 4 lung cancer than ever before, thanks to a revolution in innovative treatments, immunotherapy and precision medicine. Join us for a profoundly moving and informative episode. Sarah Craig, 31 years old with a cough and Frank Marotta, reporting to his geriatrician concerns about memory loss, share the terrifying moment they heard their diagnosis of advanced lung cancer. They graciously share their personal lung cancer journeys and where they found hope. Renowned medical oncologist Dr. Jessica Lin answers the difficult questions: How does lung cancer metastasize, and how does a doctor compassionately deliver a life-altering diagnosis? She shares her approach to guiding patients through their darkest moments. Dr. Lin also describes how cutting-edge tools like Next-Generation Sequencing (NGS) and PD-L1 testing are now standard biomarker evaluations, fundamentally shifting care from generalized chemo to truly personalized targeted therapy and immunotherapy. Learn how this new era of evaluation and treatment is bringing tangible hope to those who need it most.

How a silent killer invades our homes and our genes HOST: Hildy Grossman, CO-HOST: Jordan Rich GUESTS: Jackie Nixon, Citizens for Radon Reduction; Jane Malone, National Policy Director Indoor Environments Association; Khadijah Mitchell, Ph.D., Temple University, School of Public Health Your DNA is not a fixed blueprint. Dr. Khadijah Mitchell elucidates epigenetics, showing that our environment and behaviors can “flip switches” on our genes, turning them on or off. But what happens when that environment is toxic? Enter a silent, invisible threat: radon. This naturally occurring radioactive gas is the second leading cause of lung cancer and seeps into 1 in 15 homes. For lung cancer survivor and activist, Jackie Nixon, this statistic is deeply personal. She shares her powerful story and her fight to educate others. This podcast isn’t just a science lesson; it’s a story of survival and a crucial public health warning. Hear from environmental advocate Jane Malone on why simple testing is vital and the need for life-saving regulations that are still missing in many high-risk states. This episode is a powerful mix of cutting-edge science and real-world action. Discover how to protect your home with a simple, inexpensive kit and how you can help.

HOST: Hildy Grossman, CO-HOST: Jordan Rich GUEST: Chi Fu Jeffrey Yang. MD, Thoracic surgeon at Massachusetts General Hospital, Professor of surgery at Harvard Medical School For any cancer patient facing surgery, there are always questions and worries. Hildy interviews an outstanding thoracic surgeon at Massachusetts General Hospital, Chi Fu Jeffrey yang, MD. They discuss the current trends in lung cancer surgery, particularly the movement from taking as much tissue as possible to taking as little lung tissue as possible. This trend has not been without conflict and disagreement. Recent studies show that, for earlier stages, taking a wedge is preferable to taking an entire lobe. Dr. Yang delves into why and explains the different ways surgery is conducted. The goal of this, and all our podcasts, is to provide accurate and current information for patients, providers and caregivers. Please listen and share with anyone you know facing surgical treatment for their cancer.

From Lung Cancer Patient to Full Time Advocate HOST: Hildy Grossman, CO-HOST: Jordan Rich GUEST: Dusty Donaldson, Lung Cancer Patient Advocate, LiveLung Founder At fifty-one, Dusty’s life was a whirlwind. A mother of three, she was also juggling a full-time career and graduate school when a lung cancer diagnosis stopped everything in its tracks. Her treatment included the surgical removal of two lobes of her lung and adjuvant chemotherapy. Now, twenty years later, with no recurrence, Dusty has gone from patient to full-time advocate. Her determination has led her to establish a national lung cancer organization dedicated to creating patient and caregiver groups, offering vital education and providing community for those facing this disease. In September 2025, to celebrate survival, she’ll take off for a road trip around the US in her “Skan Van” to raise awareness about early detection and the urgent need for research funding. She’ll join Hildy in Boston for Upstage Lung Cancer’s concert in October. How did she do all this? Listen to this inspiring story.

HOST: Hildy Grossman, CO-HOST: Jordan Rich GUEST: Jacy Dawn Valeras, Award-winning Television Host, Producer, Podcaster and Music Business Executive Hildy welcomes Jacy Dawn Valeras—television host, producer, music business executive, and podcaster with over 25 years of experience in the industry. Jacy shares her life-long dream of becoming a country music singer. With her father’s encouragement, family’s support, and her own determination and talent, she succeeded in sharing the stage with some of country music’s biggest names. But just as her star was rising, a vocal cord injury forced her to stop singing—for at least a year. Overcome and unsure of her future, Jacy faced a turning point. By refusing to give up, she found a new way to channel her love for country music: writing songs and helping other artists shine. She also mastered digital marketing, launched her own successful business, and began guiding performers at every stage of their careers. Her journey didn’t stop there. Jacy now hosts a popular podcast where she interviews high-profile guests about their paths to success. What’s more, in honor of her father who ultimately lost his life to lung cancer, she works tirelessly as a passionate advocate for Upstage Lung Cancer to raise awareness and inspire hope. Tune in to hear the powerful story of a woman with true grit, resilience, and a deep love for music that never quit—even when life tried to stop her.

Voicing New Reasons for Optimism HOST: Hildy Grossman, CO-HOST: Jordan Rich GUEST: Maida Mangiameli, Dusty Donaldson, Misty Shields, MD, Ph.D., and Ann Steagall Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer with a 5-year survival rate of just 7%, a disheartening statistic. Despite this, survivors, researchers, and the medical community are actively working to create a more hopeful future. In this powerful podcast episode, we bring together a diverse team of guests to discuss stories of survival, groundbreaking treatments, and renewed reasons for hope. You’ll hear from: • Maida Mangiameli, an inspiring SCLC survivor who’s been in remission for 8 years, so far. • Dr. Misty Shields, a physician-scientist specializing in SCLC within her oncology practice who also shares a personal story. • Dusty Donaldson, a lung cancer survivor and patient-advocate whose organization provides crucial support groups for SCLC patients. • Ann Steagall, a dedicated nurse navigator who guides patients through their diagnosis and treatment journey. Join us for a lively discussion that sheds light on the progress being made and the hope that exists for those facing small cell lung cancer.

HOST: Hildy Grossman, CO-HOST: Jordan Rich GUESTS: Jaclyn LoPiccolo, MD, Ph.D., Pasi Janne, MD, Ph.D., Dana Farber Cancer Institute and Jill Feldman, EGFR Resisters Hildy opens with a powerful anecdote about an early Upstage Lung Cancer Board member whose mother, grandmother, and aunt all had lung cancer. She endured months of allergy and antibiotic treatments for a persistent cough, only for a CT scan a year later to reveal Stage 3 lung cancer. Our guest, Jill Feldman, brings a unique perspective as a third-generation lung cancer patient, with the disease present on both sides of her family. Oncologists and researchers Dr. Pasi Janne and Dr. Jaclyn LoPiccolo join in to discuss their “Inherit” study www.Inheritstudy.org, which aims to clarify the genetic risk for lung cancer, especially when there’s a family history. This vital conversation tackles the complex question of inheritance and environment in understanding lung cancer development. This vital conversation tackles the intricate interplay between inheritance and environment in understanding lung cancer development – a compelling question often raised by family members after a loved one’s diagnosis.

A Biomarker Dialogue Between Patient and Scientist HOST: Hildy Grossman, CO-HOST: Jordan Rich GUEST: Marc Muskavitch, PhD, ALK+ & Zachary Rogers, PhD, Research Fellow, Koch Institute at MIT This episode features a powerful conversation between two scientists, one now navigating life as a Stage 4 ALK+ lung cancer patient. Most lung cancer patients only learn the significance of biomarkers like ALK+, soon after their diagnosis. Our guest Marc Muskavitch, however, arrived at this knowledge with a distinct advantage: he is a scientist himself. With a background spanning drug development, biochemistry, and genetics, and holding seventeen patents, Marc’s understanding shaped his emotional and strategic response to his diagnosis and ongoing journey. His compelling conversation with scientist Zach Rogers, a previous podcast guest who addressed recurrence and drug response in lung cancer, gains even greater meaning in this context. Marc also sheds light on the significant community brought together by the ALK Positive patient organization that is now collaborating with the scientific research organization, Break Through Cancer. Our guests discuss their vision for hopeful future advancements in cancer treatment.

HOST: Hildy Grossman, CO-HOST: Jordan Rich GUEST: Zachary Rogers, Ph.D. Postdoc at MIT | American Cancer Society Fellow Lung cancer treatment is undergoing a revolution. In the last 15 years, we’ve transitioned from broad chemotherapy to precision medicine, targeting the specific genetic drivers of each patient’s cancer. This shift, along with the rise of immunotherapy, offers unprecedented hope. Today, we speak with Dr. Zachary Rogers, a post-doctoral researcher at MIT’s Koch Institute, whose work on ALK mutations illuminates these advancements. He’ll explain how targeted therapies and immunotherapies combat cancer, and delve into crucial questions: why do some patients respond while others don’t, and why does recurrence occur even after apparent remission? Dr. Rogers will also share insights into groundbreaking research on new cancer markers. Join us for a critical discussion on the future of lung cancer treatment – a conversation that provides a vital look at the forefront of cancer research.

HOST: Hildy Grossman, CO-HOST: Jordan Rich GUEST: James Hiter, Streak for A Cure James and Hildy had a similar experience in having their lung cancer found by accident. James, a “streaker” who runs daily, epitomized health. So, a lung cancer diagnosis—discovered accidentally during a bout of the flu—came as a devastating shock. A routine X-ray revealed a tumor of the size of a tennis ball. This unexpected twist led James to uncover a family history of the disease: his grandmother and great-uncle both succumbed to lung cancer. Driven by this knowledge, he joined a research study exploring the genetic links to lung cancer. James’s story is one of resilience. He shares the profound impact of lung cancer on his life, offering an “optimistic realist’s” perspective on daily life and the challenges he and his wife face. Initially declared “cured” after surgery, James’s world was rocked a year later by the cancer’s return. This time, he learned he had the KRAS biomarker, a discovery that proved crucial in guiding his treatment. He details his treatment journey, the setbacks, and the hope that came with targeted therapies. James’s story is one of resilience, hope, and the power of medical research. From accidental diagnosis to recurrence, he’s facing the ups and downs with resolute positivity. Hear how he’s using his experience to inspire others through “Streak for A Cure.” Don’t miss this powerful podcast!”

HOST: Hildy Grossman, CO-HOST: Jordan Rich GUEST: Zofia Piotrowska, MD, MHS, Massachusetts General Hospital This podcast delves deeper into the evolving understanding of the HER2 biomarker in lung cancer, twenty years after its discovery. We’re joined by Dr. Zofia Piotrowska, renowned oncologist and researcher at Massachusetts General Hospital, to build on our previous discussion, “HER2 Isn’t Just About Her!” Dr. Piotrowska explores the intricate nuances of HER2 in lung cancer, explaining how subtle genetic variations can significantly impact treatment outcomes. While HER2 biomarkers are more frequently observed in non-smokers, women, and younger patients, it’s crucial to remember that anyone with lungs can develop lung cancer. Of critical importance in diagnosis and treatment decisions is comprehensive biomarker testing. This valuable information empowers clinicians to tailor treatment plans with precision. This episode highlights the remarkable progress made in precision medicine in combating HER2-positive lung cancer, offering renewed hope for patients, their loved ones, and the entire medical community.

HOST: Hildy Grossman, CO-HOST: Jordan Rich GUEST: TERRI CONNERAN, Founder of KRAS Kickers Imagine facing five recurrences of cancer in seven years. Terri Conneran did, and she turned her adversity into a powerful force for change. Terri embodies the strength of the will to defy the odds of a cancer diagnosis and emerges as a beacon of hope for lung cancer patients. Despite multiple recurrences and navigating a challenging diagnostic journey, she remains resilient and determined to gather information, learn about research and advocate for others who have a KRAS biomarker. Terri founded KRAS Kickers to create a community for patients and families to have a place for support and gathering knowledge during diagnosis and treatment for cancer with a KRAS mutation, the most common biomarker responsible for the three deadliest cancers: lung, pancreatic and colon. Terri’s story is deeply personal, yet her fight is inspirational. She travels the world to meet with KRAS Kicker groups, researchers and providers to help revolutionize treatments. This episode is a testament to the power of hope and the power of the human spirit to kick cancer. Be sure to listen and share this podcast.

HOST: Hildy Grossman, CO-HOST: Jordan Rich GUESTS: Carl Gay, MD, MD Anderson, Misty Shields, MD, Ph.D., Indiana University Simon Comprehensive Cancer Center. Hildy shares her experience of losing a friend who was diagnosed with neuroendocrine tumors of the gastrointestinal system. Knowing that neuroendocrine cells are present in the lungs prompted Hildy to wonder if lung cancer drugs would possibly be viable in treating her friend’s condition. This podcast looks at small cell lung cancer which is a kind of aggressive neuroendocrine tumor and less aggressive, carcinoid neuroendocrine tumors. Experts Dr. Carl Gay and Dr. Misty Shields discuss how little is known about the neuroendocrine system, even among oncologists. Neuroendocrine small cell tumors in the lungs and other areas of the body are associated with tobacco use and vaping. The less aggressive, low grade, carcinoid tumors have unclear causes. The discussion includes how these tumors are diagnosed, challenges for treatment, drug resistance and recurrence. Our guests also highlight the importance of research, and new therapies that give hope to these patients.

HOST: Hildy Grossman, CO-HOST: Jordan Rich GUESTS: Jaime Cheah, Ph.D., Director of Collaborative Screening in the Center for the Development of Therapeutics at the Broad Institute and Jane Wilkinson, co-founder and president of CANCollaborate Our guests, Jane Wilkinson and Jaime Cheah join the conversation to tell us about some incredible work to expand the use of a drug beyond its original treatment target. Jane Wilkinson discusses why this is not only important for lung cancer, but particularly in rare cancers for which the time and cost of developing new drugs is prohibitive. Repurposing drugs is a powerful approach to developing new therapies, because they have already been approved by the FDA and been shown to be safe and effective for at least one indication. Jaime Cheah discusses the work at the Broad Institute at Massachusetts Institute of Technology, in terms of how drugs are repurposed and the scale of this remarkable process. You won’t want to miss how thinking so creatively leads to the beginning of a new drug discovery path.

HOST: Hildy Grossman, CO-HOST: Jordan Rich GUESTS: Geoff Oxnard, MD, VP Clinical Development, Global Head Thoracic Cancer | Thoracic Oncologist, Boston Medical Center With so many misunderstandings about clinical trials, this podcast aims to clarify what a clinical trial is, how they have changed over time, why it is important to inform patients about them and how to increase access. With only about 7% participation in clinical trials by patients, the question is how to make trials more available to patients. Dr. Geoffrey Oxnard, VP Clinical Development, Global Head Thoracic Cancer, Lilly, is our guest. He is both a treating oncologist as well as a scientist helping to develop new drugs to treat cancer. He discusses different phases in clinical trials, how to partner with his patients in making decisions about whether to join a new trial, and how to expand access to trials to diverse populations. Listen now and learn more.

HOST: Hildy Grossman CO-HOST: Jordan Rich GUESTS: David Barbie, MD and Elliott Brea MD, Ph.D. As Albert Einstein said, “If you can’t explain it simply, you don’t understand it well enough.” That said, our guests on this podcast share groundbreaking research that investigates new ways of using one’s own immune system to fight cancer. Understanding how immunotherapy works is a complicated topic. Our guests, David Barbie, MD and Elliott Brea, MD, PhD of Dana Farber Cancer Institute, do a masterful job in managing to simplify concepts, and in the most enjoyable way. They discuss the workings of immunotherapy and groundbreaking directions within this form of treatment, simplifying terms even the best educated strain to understand. Take a listen now.

HOST: Hildy Grossman CO-HOST: Jordan Rich GUESTS: Francine Jacobson, MD, MPH, Brigham and Women’s Hospital, Boston The process of being diagnosed and treated for lung cancer is often an arduous one. Hildy discusses her own winding road – how slipping on the stairs while wearing new shoes ultimately led to diagnosis and successful treatment. The accidental discovery of her tumor highlights the value of persistence by patients. With our guest, thoracic radiologist, Francine Jacobson, MD, we discuss various ways patients and their families can prepare for diagnosis and treatments. Knowing what to expect can reduce anxiety and minimize risks that patients will avoid or postpone procedures. Dr. Jacobson offers insights into preparing for CT scans, other diagnostics, and radiology treatments. Equally important is preparing family members or other caregivers to support and join the patient on their journey. Additional issues are considered, such as disparities in access to treatment, educational, racial, and financial backgrounds.

HOST: Hildy Grossman CO-HOST: Jordan Rich GUESTS: Jacob Sands, MD and Julia Rotow, MD, Dana Farber Cancer Institute Do you worry about cancer? Do you, or does someone you love, have cancer? Our guests today explore the often-worrisome journey from screening and diagnosis to treatment. This podcast features a thoughtful conversation among oncologists who share various options for diagnosis and treatment for their patients. They address what’s necessary to screen for lung cancer, what are the limits for screening, concerns about the presence of microscopic disease, how surgery and radiation can be curative, when drug treatment can be used along with surgery to improve outcomes, what pharmaceutical treatments are available, when to escalate treatment, or not and more. This valuable and hopeful conversation addresses current cancer care, as well as possibilities in future care, including the development of new technologies. You’ll want to listen and share this information with someone you know who is facing and managing cancer.

HOST: Hildy Grossman CO-HOST: Jordan Rich GUESTS: Cheryl Davis, of Red Thred Solutions; Lauren Coye, Patient and Patient Advocate What often goes unheard in medical situations is the patient’s voice. Our guests have a lot to say about this matter. Cheryl Davis has extensive experience in patient advocacy in the pharmaceutical industry. Now she aids biopharma, biotech and patient advocacy organizations in improving their practices, communications, and partnerships for better healthcare outcomes. She discusses how listening to patients’ voices shows three general types of patients and their behaviors in medical circumstances. What does it mean to have a voice? Lauren Coye describes her experience of having been diagnosed with lung cancer at age twenty-four after years of symptoms. Her resilience and determination are an inspiration.

HOST: Hildy Grossman, Co-Host: Jordan Rich GUESTS: Chi Fu Jeffrey Yang, MD with Alexandra Potter and Deepti Srinivasan Our podcasts have focused on disparities in healthcare, particularly in Hispanic, Asian, and rural communities. This podcast considers the Black community in the US, and in particular, black women. What do we know about lung cancer differences in the black community vs the white community? Well, we know that both black men and women are less likely to be diagnosed at an early stage where lung cancer is most treatable. So, survival rates in the black community are lower than in the white community. Our guests today are working hard on a research project to address this disparity by bringing information and improving access to CT scans for the community of black women. This group is often ineligible for this diagnostic tool because they don’t meet the guidelines based on the National Lung Cancer Screening Trials. Learn more and why this project is so important. Our guests today, Dr. Chi Fu Jeffrey Yang, Alexandra Potter and Deepti Srinivasan of Mass General Hospital are working hard on research into the community of Black Women and how to facilitate their participation in low dose lung cancer screening.

HOST: Hildy Grossman, Co-Host: Jordan Rich GUESTS: Jacqueline Nixon and Gloria Linnertz Radon is a radioactive gas released in rocks and soil, possibly in your home or where you work. It’s odorless, tasteless, and invisible and can seep up through the ground and circulate into the air. As a result, Radon can enter homes through cracks in floors, walls, or foundations, and collect inside of homes and other buildings. Unfortunately, Radon is a major cause of lung cancer. Scientists estimate that there are 15,000 to 22,000 lung cancer deaths in the United States each year related to radon. Both Jacqueline Nixon and Gloria Linnertz represent an organization, Citizens For Radioactive Radon Reduction. Gloria discusses how learning that her husband, Joe, had late-stage lung cancer attributable to the skyrocketing measure of radon in her home changed her life. Although Joe lost his life to lung cancer, Gloria was tireless in demanding that politicians create bills addressing the safest amount of radon for homes on a local and state level. Jacqueline’s story is one of a survivor whose lung cancer was attributed to unacceptable levels of radon in her apartment. She too took action and created a campaign of awareness. You’ll find answers to questions about acceptable levels of radon, how to test for radon, and how to get rid of it if necessary. This podcast is so important and could save a life.

What Women Need to Know About Lung Cancer Host: Hildy Grossman with Jordan Rich, co-host Guest: Narjust Duma Flores, MD Lung Cancer has a reputation of being a man’s disease. Today this notion couldn’t be further than the truth. Lung cancer is the number one cancer killer of women as well as men, taking more women’s lives than breast, ovarian, and uterine cancers combined. It’s our privilege is to have international lecturer, researcher and oncologist, Dr. Narjust Flores, as our guest to help us learn more about how women and men differ in the incidence and expression of lung cancer. She’ll discuss the significant finding that there is an increase in lung cancer diagnoses in women, while at the same time a decline in men. We’ll discuss the emerging data demonstrating sex-specific susceptibility, prognosis, and treatment of lung cancer. Dr. Flors will also speculate on why the steepest increase in incidence of lung cancer is among non-smoking women. This is a fascinating and vital conversation.

HOST: Hildy Grossman, Co-Host: Jordan Rich GUESTS: Pasi Janne, MD, Ph.D., Director, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, and the Scientific Director of the Belfer Center for Applied Cancer Research Gabrielle Goodman, HER2 patient Bill Brand, HER2 patient Caren Suesserman, Exon 20 Group Virtual Meeting Leader and Patient Advocate Most people are familiar with HER2 presence in breast cancer. In this podcast we discuss the rare but significant presence of HER2 in lung cancer. We’re honored to have one of the original investigators in the discovery of the EGFR mutation. Dr. Pasi Janne has also led the development of strategies for treating patients with HER2 and other biomarkers. He discusses the importance of finding HER2 in lung cancer and how this knowledge impacts treatment choices. Bill Brand and Gabrielle Goodman share their own, unique stories and of learning of their HER2 biomarker helps direct their treatment. They also agree that having found the organization, EXON20 has helped them gain support and not feel alone. Finally, Caren Susserman describes how she leads weekly Zoom meetings for the EXON20 group for those with HER2. The broad range of services help to ease living with this rare disease.

HOST: Hildy Grossman, Co-Host: Jordan Rich GUESTS: Anthony Sireci, MD, and Hilary Hammell, MD In this podcast, we ask the question, “Along with an accurate cancer diagnosis, why is comprehensive biomarker testing so important? Our guest, Dr. Anthony Sireci, vice president of clinical biomarker and diagnostics development at Loxo@Lilly, has devoted his career to biomarker testing and development. He shares his interest in precision medicine and talks about what inspired him to get involved in this field. He helps us understand why comprehensive biomarker testing is so important when considering treatment options for cancers, including non-small cell lung cancer (NSCLC). Our other guest, Hilary Hammell, is a physician herself, and has been diagnosed with advanced stage lung cancer. She shares her own experience about learning she has the RET positive biomarker. She adds that knowing her own biomarker guided her to a treatment that helped to “save her life.” This episode is important for understanding how precision medicine works, how it’s different from other current treatments, and how patients and their families can address comprehensive biomarker testing with their physician. With this fascinating and informative conversation, the question remains how to increase patient’s access to biomarker testing.

Immunotherapy is a cutting-edge treatment for lung cancer. Learn all about it. HOST: Hildy Grossman, Co-Host: Jordan Rich GUESTS: David Barbie, MD, Oncologist, Dana Farber Cancer Institute We often hear about our immune system, but outside of science class, few of us understand how it works. Whether your last brush with science was high school biology or you are a career scientist, there is much to learn from Dr. David Barbie. He discusses the role our immune system plays as a protector against infection, and how understanding the immune system’s mechanisms of action has led researchers to develop immunotherapies to treat cancer. He also answers how advanced lung cancer patients and their treatment team choose among chemotherapy, targeted therapy, or immunotherapy. This is a podcast you will want to be sure to listen to.

HOST: HILDY GROSSMAN   CO-HOST: JORDAN RICH GUEST:  RAYMOND OSAROGIAGBON, MD, FACP, Director of the Multidisciplinary Thoracic Oncology Program at Baptist Cancer Center in Memphis, Tennessee. Many of us living in urban areas have some awareness and experience of barriers to healthcare, but we seldom consider the obstacles that face people living in rural areas. This is especially true where lung cancer is involved. Our guest, Dr. Osarogiagbon began his career in lung cancer in the 1990s, and at that time, a lot of folks questioned his decision to focus on a disease where life expectancy was so poor. He shares with us what inspired him to work with overlooked poor, rural and black communities. He also discusses the importance of research, what his research is currently focused on and where it continues to develop. Dr. Osarogiagbon talks about the impact of geography on a person’s health. For example, his practice is in Memphis, Tennessee, in the heart of the Southeastern US, where the lung cancer burden is the greatest and where outcomes tend to be the worst. The complexities in identifying and treating people with cancer in rural areas can have a substantial impact on health outcomes. Dr. Osarogiagbon also discusses some of the similar issues experienced by black communities in rural and urban areas. This is an important conversation you won’t want to miss.

HOST: Hildy Grossman, Co-Host: Jordan Rich GUESTS: Jacob Sands, MD, Oncologist, Dana Farber Cancer Institute, and Andrea McKee, MD, Chair of Radiation Oncology, Lahey Hospital & Medical Center (LHMC) In previous Backstage @ Upstage podcasts, we’ve discussed the importance of low dose CT scans to detect lung cancer early. Both of today’s guests are dedicated to helping to make lung cancer screening available for all who are eligible. Dr. McKee initiated “Rescue Lung, Rescue Life,” a program to broaden access to lung cancer screening without cost to patients. She discusses what prompted her to start this program at her own center and her work to make this program available throughout the country. Dr. Sands discusses the low percentage of people nationally who take advantage of lung cancer screening—only about 3%! Here in Massachusetts, we are leading the pack, but the percentage of people getting scans is only 17%. We all agree these are failing grades. We need to do better. This podcast is an important conversation about what opportunities we can create to help save lives. Years ago, lung cancer was seen as a death sentence. Now, lung cancer screening can detect the disease early, when lives can be saved and extended. Don’t miss this fascinating exchange.

Host: Hildy Grossman Co-Host Jordan Rich Guest: Francine Jacobson, MD, MPH Dr. Francine Jacobson discusses the value of screening for early detection of lung cancer. From the perspective of patients and care givers, facing radiation can be concerning. Dr. Jacobson discusses the lowering doses of radiation to help find lung cancer early, with the benefit of identifying and treating the disease at the earliest possible time. What’s new? There is more understanding of early lung cancer and how to approach it for treatment. Artificial Intelligence is in the news, and now has the potential to predict the presence of lung cancer. New technologies and scanning abilities will help to make lung cancer a chronic disease. This podcast helps to demystify the process of scanning and treating lung cancer with radiation. This includes addressing fears and scanxiety associated with scans and treatment. The questions and answers raised in this episode focus on the concerns of patients, family members and caregivers.

HOST: HILDY GROSSMAN CO-HOST: JORDAN RICH GUEST: GLORIA ZHANG, Executive Director of Strategic Alliances at New Tang Dynasty The Asian and Pacific Islander population represents over 30 countries and contains ethnic groups that speak more than 100 different languages! Chinese- Americans represent over 24% of the Asian-American population and are the focus audience for our guest, Gloria Zhang. She is the executive director of strategic alliances at New Tang Dynasty, an independent, nonprofit television network that provides a wide range of programs for the Chinese-American community and around the world. The network aims to educate its audience about the higher incidence of lung cancer among Southeast Asian Americans compared to White Americans. In fact, the group with the greatest increase in lung cancer is with non-smoking women. Be sure to listen to this important discussion. podcast.

HOST: HILDY GROSSMAN CO-HOST: JORDAN RICH GUESTS: KEVIN SALINAS, MD AND FRACINE JACOBSON, MD, MPH By 2060, the Census Bureau projects that the Hispanic/Latino population will make up almost one third of the US population. In addition, the Hispanic population is a diverse group who trace their heritage to more than 20 Spanish-speaking countries, regardless of race. Kevin Salinas, MD is a Harvard Medical School student in his final year. His family immigrated from Mexico and they continue to live in a small town in the US. He describes his family background and his focus on issues that face Hispanics in access to health care as well as considerations in receiving care. Thoracic radiologist, Francine Jacobson, MD, MPH joins the discussion regarding poverty and lack of health insurance, language barriers, cultural barriers and limited access to standard care. For undocumented individuals, there is anxiety about deportation if they access medical treatment. In our country of diversity, we all grow in understanding how cultures within the general population view lung cancer and treatment. This is a discussion you won’t want to miss.

Hosts: Hildy Grossman with Jordan Rich co-host Guests: Susan Smedley, Founder, Resilient Souls Anyone receiving a cancer diagnosis wonders what else they can be doing to cope that isn’t dependent on a physical protocol. Too often medical treatment overlooks the emotional component of diagnosis and treatment in facing lung cancer. Patients undergo the emotional and psychological impact of feeling walloped by their illness, often by experiencing insomnia, anxiety and depression. Our guest, Susan Smedley, was diagnosed with lung cancer when she was 32 years old. She discusses her process of transitioning from the shock of learning she had lung cancer at such an early age, with an 11-month-old child, to looking for healthy ways to cope using mindfulness, joining advocacy efforts and now creating her own organization to focus on wellness while facing trauma and challenging medical circumstances. This uplifting podcast is for everyone to help show how gravitating toward wellness efforts can significantly improve the quality of life.

Lung Cancer detected early saves lives. Hosts: Hildy Grossman with Jordan Rich co-host Guests: Francine Jacobson, MD, MPH; Dusty Donaldson; Dan Cardigan, MD Three exceptional guests join the conversation about the importance of lung cancer screening from a medical and personal point of view. Dr. Francine Jacobson is a founding director of the lung cancer program at Brigham and Women’s Hospital Health Care in Boston. As a thoracic radiologist, she describes CT scans, what patients need to know about the process of having a scan and what can be learned from them. Dan Cardigan, MD continues the discussion as a primary care physician and also as someone diagnosed with Stage 4 lung cancer. In addition, patient advocate and lung cancer survivor Dusty Donaldson shares her experience of learning that she had lung cancer at an early stage. She tells how that experience has fueled her commitment to spending her life advocating for patients with lung cancer. This is a dynamic, encouraging and convivial discussion you won’t want to miss.

Host: Hildy Grossman Co-Host: Jordan Rich Guest: Bill Shields, Journalist and TV Field Reporter Bill Shields has had a celebrated career as a Boston area broadcaster for over forty years. Originally from Texas, Bill began his career at a local TV station before moving to Boston for a job at WBZ-TV where he happily spent his career after falling in love with the city. Ten years ago, Bill was diagnosed with Stage 3B small cell lung cancer. He describes how he was successfully treated at the time and lived cancer free until last year when he received a new diagnosis of non-small cell lung cancer. Bill describes his cancer journey, his experience as a reporter and how important humor is to living a full life. Bill’s own words show his grace, humanity and ability to find joy in life, no matter the hardships. You’ll hear why he’s so beloved by all who worked with him and all who watched him on the news.

Hosts: Hildy Grossman with Jordan Rich co-host Guests: Francisco J. Sánchez-Rivera, Ph.D. and Jane Wilkinson Our prior podcast, “What Did the Human Genome Project Ever Do For Us?” was so exciting and enjoyable that we all felt there was no stopping the conversation with just one podcast. We just had to go on. Our guest, Jane Wilkinson actually worked on the original Human Genome Project and was able to share her experiences and explain this blockbuster effort in such a down-to-earth way that it transformed this complicated topic to a very accessible one. Our other guest, Francisco Sanchez-Revera, Ph.D. began to describe some of the medical consequences that resulted from this work. Today’s podcast continues with Francisco’s highlighting some of the amazing work being conducted in his lab at Massachusetts Institute of Technology. His work is focusing attention on the cause of cancer as well as specifically on the cause of lung cancer. Listen to this important and wonderful conversation!

Hosts: Hildy Grossman with Jordan Rich co-host Guests: Jane Wilkinson and Francisco J. Sánchez-Rivera, Ph.D. In this podcast, we do our utmost to help make a complicated topic something we can all understand. Many of us have heard about the Human Genome Project (HGP), but few of us could explain it to someone else. There are terms that are basic to the project, such as “genes”, “genome”, “DNA” “Sequencing” and – no! Wait a minute! Don’t be frightened! Jane Wilkinson, Executive Director of MIT’s Koch Institute for Cancer Research shares her experience of being a part of the original team unraveling the human genome. She clarifies some of the basic ideas behind the HGP, and describes her specific role. Her exciting explanation of the development and significance of this amazing project directly impacts the research of our other guest, professor of biology at MIT, Francisco Sanchez- Rivera, PhD. He explains, in a very understandable way, how his laboratory is investigating the origins of cancer and how the knowledge of the human genome has resulted in finding and targeting treatment of lung, and other cancers. This project is a perfect compliment to our other podcasts looking at biomarker testing. Don’t miss this thoroughly enjoyable and informative discussion.

Hosts: Hildy Grossman with Jordan Rich co-host Guests: Heather Smith Heather Smith was only 34 when she was diagnosed, simply by accident, with lung cancer. It had already spread to other areas of her body. After experiencing this frightening curve ball, she was grateful that biomarker testing revealed that she was ALK+. Knowing this genetic mutation, she could be treated with targeted therapies that specifically aim at this genetic mutation. Heather discusses her diagnosis, the course the disease has taken and the challenges she continues to face. Once her disease progressed, she developed seizures, and after one of the seizures, she fell onto her concrete patio and was hospitalized. While hospitalized, she resolved to not be taken down by her circumstances. “I didn’t want to merely survive my cancer diagnosis. No! I wanted to thrive with cancer.” Heather got up from being knocked down by her lung cancer diagnosis, more determined than ever. She became a life coach. She creatively decided to share what she’s learned, to help other lung cancer patients face adversities. Heather is empowered by knowing: “I’m living my best life as a kick a** cancer thriver!” Her message is powerful for all of us. Do not to take threats lying down!

Co-Hosts: Hildy Grossman and Jordan Rich Good friends, Hildy Grossman and Jordan Rich put their heads together to talk about the importance of creativity when initiating innovative new research. They compare this experience in the lab to one of a songwriter and composer looking at a blank sheet of paper to come up with a new song. Upstage Lung Cancer has always taken pride in being innovative and outside of the box where lung cancer advocacy is concerned. Song requires a healthy use of lungs, and ULC produces concerts to share the joy and vitality of music while bringing information to the audience about lung cancer. This is a bit like Mary Poppins’ concept of “a spoonful of sugar makes the medicine go down”. Thus, the dynamic duo delightfully discuss ULC’s musical programs as well as the innovative research and scientists our organization support.

Listen to caregivers for spouses diagnosed with rare biomarkers HOST: HILDY GROSSMAN CO-HOST: JORDAN RICH Guests: Marcia Horn, JD. President and CEO at ICAN, International Cancer Advocacy Network and Executive Director, Exon 20 Group; Caren Suesserman, Care Partner, Spouse, and Patient Advocate, Exon 20 Group; Sandy Kitchner, Care Partner, Spouse and Patient Advocate, Exon 20 Group In our latest podcast focusing on biomarkers, we talk with Marcia Horn, from ICAN, the International Cancer Advocacy Network, and who serves as executive director of the Exon 20 Group. Previously as part of our podcast series, we’ve discussed the biomarker EGFR and how drug therapies have been developed to directly target this mutation. In this podcast, Marcia discusses rare Exon 20 Insertion Mutations found primarily in Non Small Cell Lung Cancer, but also found in many other cancer types. The problem is, these rare mutations do not respond like classical EGFR mutation to traditional targeted therapies. Also, Non Small Cell Lung Cancer patients can also be diagnosed with a HER2 Exon 20 insertion mutation, and those insertion mutations in fact, comprise around 50% of all HER2 lung cancer mutations. Our guests, Caren Suesserman and Sandy Kitchner, have both been care partners for spouses who were diagnosed with EXON 20 insertion mutations. They discuss what can be helpful for those caring for loved ones with advanced disease, and how their own experiences have led them to advocate for other Exon 20 Group lung cancer patients.

How a positive attitude and biomarkers can guide your journey Hosts: Hildy Grossman with Jordan Rich Guests: Jill Feldman and Ivy Elkins with Dann Wonser, EGFR survivors Two of our other Podcasts have emphasized how important it is to get your tumor tested for biomarkers. We focused on one specific biomarker, EGFR, with two outstanding guests who were both diagnosed with lung cancer and had this mutation. Jill Feldman and Ivy Elkins, of the EGFR Resisters advocacy group return to share more about the work of their organization to help patients and their families. They bring along another member of the EGFR Resisters community, Dann Wonser. Dann shares his own experience being diagnosed with lung cancer, by accident, in 2006. Being free of disease for five years, in 2011 he was diagnosed with advanced stage lung cancer. Dan’s story is inspirational, and he conveys his perspective of hope and fortitude as he continues to be active in his treatment. One way of coping with difficulties is to take action. Dann, Jill and Ivy are inspirational examples.

Jill Feldman and Ivy Elkins Hosts: Hildy Grossman with Jordan Rich Guests: Jill Feldman and Ivy Elkins Two outstanding and determined women share how their lung cancer diagnosis, along with the ability to detect a particular biomarker, EGFR, has had a significant effect on the course of their lives. Biomarkers indicate alterations in your DNA that may drive a tumor. Using biomarker testing, it’s possible to refine diagnostic information to help select treatments to target directly that alteration. Both Jill Feldman and Ivy Elkins have channeled their experience as lung cancer survivors and advocates, to create a patient-centered organization, EGFR Resisters. This organization supports and notifies the EGFR-positive, lung cancer community about the latest information in diagnosis, research and treatment. They encourage us to persevere, and to support continued research to make lung cancer a manageable, chronic disease.

HOST: HILDY GROSSMAN CO-HOST: JORDAN RICH GUESTS: Jacob Sands, MD, and Catherine Meador, MD, Ph.D. Small cell lung Cancer (SCLC) is often called the smoker’s lung cancer, since it is most often diagnosed in heavy smokers. While this type of lung cancer is less prevalent than non-small cell lung cancer (NSCLC), it’s more aggressive. Two dedicated and experienced physicians who specialize in treating lung cancer, Dr. Jacob Sands and Dr. Catherine Meador, offer their fascinating insights about the importance of getting a low-dose CT scan when there is a history of heavy smoking. There are often powerful emotional reactions that accompany a SCLC diagnosis, including fear, anxiety, stigma and guilt. It’s important for patients and medical professionals to address these emotional reactions, assuring that they are reasonable under the circumstances. New and exciting research offers new prospects to live with SCLC. Diagnostic and treatment options include biomarker testing, targeted therapies, immunotherapy, combinations of drug with chemotherapy, and clinical trials. The conversation in this podcast emphasizes that each person is a unique individual who should not be swept away by statistics.

Host: Hildy Grossman Co-Host: Jordan Rich Guests: Jane Wilkinson, Tarek Fadel, Jesse Kirkpatrick, Christina Cabana Imagine the scene of a murder. Detectives are called in to figure out how to solve the case. Sherlock Holmes was created by Sir Arthur Canon Doyle. Holmes was the most famous mastermind detective, whose powers of observation led him to uncover clues and evidence that others would miss. Upstage Lung Cancer’s mission is to support research that develops innovative techniques to find lung cancer at the earliest possible time. To date, there are no reliable, easily available and inexpensive ways to do this. We have been supporting a team from MIT’s Koch Institute for Integrative Cancer Research who use state-of-the-art research methods that creatively wed science and engineering to discover the presence of cancer. They use nanotechnology to study in real time tiny nano particles that are one hundred to ten thousand times smaller than human cells. This new method has the potential to detect lung cancer during the earliest stages of progression. What would Sherlock Holmes think? Listen to this fascinating discussion to learn more. “It’s my business to know what other people don’t know.” -Sir Arthur Canon Doyle, The Blue Carbuncle